MedWatch

Novo rival disappoints in major cardiovascular study

A study of more than 14,000 diabetes patients shows that AstraZeneca’s GLP-1 drug Bydureon has not managed to lower the risk of cardiovascular events. Thus, Novo Nordisk is still the only company with a drug from this class to show an effect on CV risk. But now, all eyes are on Eli Lilly.

Foto: Colourbox

The British-Swedish drug group AstraZeneca has reported disappointing results from a major study of one of its most important diabetes drugs, it reveals in a press release.

Here, AstraZeneca presents the topline data from the phase III/IV study Exscel with the company’s GLP-1 receptor agonist Bydureon (long-acting exenatide). The study compared treatment with Bydureon relative to placebo in more than 14,000 diabetes patients from 35 different countries.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier